T. Rowe Price Associates
IRON icon

T. Rowe Price Associates’s Disc Medicine IRON Stock Holding History

T. Rowe Price Associates’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.1M Sell
1,549,350
-148,655
-9% -$10.3M 0.01% 614
2025
Q4 		$135M Buy
1,698,005
+371,576
+28% +$31.4M 0.01% 568
2025
Q3 		$87.7M Sell
1,326,429
-189,196
-12% -$11.3M 0.01% 650
2025
Q2 		$80.3M Buy
1,515,625
+157,371
+12% +$7.39M 0.01% 617
2025
Q1 		$67.4M Sell
1,358,254
-36,383
-3% -$2.02M 0.01% 634
2024
Q4 		$88.4M Buy
1,394,637
+262,690
+23% +$15.2M 0.01% 593
2024
Q3 		$55.6M Buy
1,131,947
+9,753
+0.9% +$458K 0.01% 728
2024
Q2 		$50.6M Buy
1,122,194
+177,981
+19% +$6.05M 0.01% 721
2024
Q1 		$58.8M Buy
944,213
+353,382
+60% +$22.9M 0.01% 686
2023
Q4 		$34.1M Buy
590,831
+63,092
+12% +$3.23M ﹤0.01% 807
2023
Q3 		$24.8M Buy
527,739
+325,069
+160% +$16.3M ﹤0.01% 871
2023
Q2 		$9M Buy
+202,670
New +$7.19M ﹤0.01% 1093
2021
Q2 		– Sell
-25,000
Closed -$9.65M – 2939
2021
Q1 		$9.65M Buy
+25,000
New +$11.2M ﹤0.01% 1400

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates's IRON Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Disc Medicine (IRON) stake by 8.8% in Q1 2026, selling an estimated $10.3M and leaving 1,549,350 shares worth $99.1M. The position accounts for 0.01% of the portfolio, ranked #614.

T. Rowe Price Associates first reported a position in IRON in Q1 2021 and has held it in 13 quarters since. The position peaked at $135M in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • T. Rowe Price Associates held 1,549,350 shares of Disc Medicine worth $99.1M as of Q1 2026.
  • T. Rowe Price Associates sold 148,655 Disc Medicine shares in Q1 2026, an estimated $10.3M.
  • Disc Medicine made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #614 holding.
  • T. Rowe Price Associates first reported a position in Disc Medicine in Q1 2021 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Disc Medicine position peaked at $135M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.